Is survival enough for myelodysplastic syndromes?

Leuk Res. 2009 Aug;33(8):1017-8. doi: 10.1016/j.leukres.2009.02.001. Epub 2009 Mar 5.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Adult
  • Aged
  • Antilymphocyte Serum / administration & dosage
  • Cytarabine / administration & dosage
  • Disease-Free Survival
  • Enzyme Inhibitors / administration & dosage
  • Female
  • Germany
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / mortality*
  • Myelodysplastic Syndromes / therapy*
  • Registries
  • Retrospective Studies
  • Risk Factors
  • Stem Cell Transplantation
  • Survival Rate
  • Thalidomide / administration & dosage
  • Transplantation, Homologous
  • Valproic Acid / administration & dosage

Substances

  • Antilymphocyte Serum
  • Enzyme Inhibitors
  • Immunosuppressive Agents
  • Cytarabine
  • Thalidomide
  • Valproic Acid